Ganitumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Ganitumab
DrugBank Accession Number
DB12205
Background

Ganitumab has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, Breast Cancer, Breast Tumors, and Breast Neoplasms, among others.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Ganitumab
External IDs
  • AMG 479
  • AMG-479
  • AMG479

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Ganitumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Ganitumab.
AducanumabThe risk or severity of adverse effects can be increased when Ganitumab is combined with Aducanumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ganitumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Ganitumab.
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
CK1441RCZ8
CAS number
905703-97-1

References

General References
Not Available
PubChem Substance
347911298
Wikipedia
Ganitumab

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
3Active Not RecruitingTreatmentMetastases to lung / Metastatic Ewing Sarcoma / Metastatic Malignant Neoplasm in the Bone / Metastatic Malignant Neoplasm in the Bone Marrow / Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone / Peripheral Primitive Neuroectodermal Tumor of Soft Tissues1somestatusstop reasonjust information to hide
3TerminatedTreatmentAdvanced Malignant Neoplasm / Advanced Solid Tumors / Bone Metastases / Cancer / Cancer Patient / Endocrine Cancer / Metastatic Cancer / Oncology / Pancreatic Adenocarcinoma / Pancreatic Cancer / Pancreatic Metastatic Cancer / Solid Tumors1somestatusstop reasonjust information to hide
2CompletedTreatmentAdvanced Solid Tumors / Carcinoids / Colorectal Cancer / Locally Advanced / Lymphoma / Metastatic Cancer / Non-Small Cell Lung Cancer (NSCLC) / Sarcomas / Solid Tumors1somestatusstop reasonjust information to hide
2CompletedTreatmentAskin's Tumors / Desmoplastic Small Round Cell Tumor (DSRCT) / Estraosseous Ewing's Tumor / Ewing's Sarcoma / Primitive Neuroectodermal Tumor / Sarcomas1somestatusstop reasonjust information to hide
2CompletedTreatmentCarcinoid Tumors / Neuroendocrine Tumors / Pancreatic Neuroendocrine Tumor1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at October 20, 2016 21:36 / Updated at February 18, 2023 02:02